Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats

Xenobiotica

Volumn 39, Issue 2, 2009, Pages 162-170

  Kurosawa, S ^a   Uchida, S ^a   Ito, Y ^a   Yamada, S ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Cytochrome P450 (CYP) 3A; Midazolam; Pharmacokinetics; Ursodeoxycholic acid (UDCA)

Indexed keywords

CYTOCHROME P450 3A; DEXAMETHASONE; MESSENGER RNA; MIDAZOLAM; NITRAZEPAM; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HYDROXYLATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; HALF-LIFE; HYDROXYLATION; INJECTIONS, INTRAVENOUS; INTESTINES; KINETICS; LIVER; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; MIDAZOLAM; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; URSODEOXYCHOLIC ACID;

RATTUS;

EID: 61649089256     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802621680     Document Type: Article

References (37)

1. Aukee S, Venho VM, Jussila J, Karjalainen P. 1975. Drug absorption in patients with T-tube after cholecystectomy. Ann Clin Res 7(1):42-46.
2. Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Verstuyft C, Eichelbaum M, Fromm MF. 2006. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther 79(5):449-460.
3. Beuers U, Boyer JL, Paumgartner G. 1998. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28(6):1449-1453.
4. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome' U, Einarsson C, Diczfalusy U. 2001. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 276(42):38685-38689.
5. Dundee JW, Halliday NJ, Harper KW, Brogden RN. 1984. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 28(6):519-543.
6. Eeckhoudt SL, Horsmans Y, Verbeeck RK. 2002. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32(11):975-984.
7. Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. 2000. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 30(10):943-953.
8. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. 2002. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32(3):165-206.
9. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47(9):1643-1653.
10. Gutzler F, Zimmermann R, Ring GH, Sauer P, Stiehl A. 1992. Ursodeoxycholic acid enhances the absorption of cyclosporine in a heart transplant patient with short bowel syndrome. Transplant Proc 24(6):2620-2621.
11. Harris RZ, Benet LZ, Schwartz JB. 1995. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50(2):222-239.
12. Kobayashi K, Urashima K, Shimada N, Chiba K. 2002. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63(5):889-896.
13. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ. 2002. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302(3):1228-1237.
14. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. 2002. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72(6):718-728.
15. Li AP, Kaminski DL, Rasmussen A. 1995. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104(1-3):1-8.
16. Lindholm A, Henricsson S, Dahlqvist R. 1990. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 29(5):541-548.
17. Maier A, Zimmermann C, Beglinger C, Drewe J, Gutmann H. 2007. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 150(3):361-368.
18. Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y. 2004. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 309(3):1282-1290.
19. Matsubara T, Yoshinari K, Aoyama K, Sugawara M, Sekiya Y, Nagata K, Yamazoe Y. 2008. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab Disposit 36(10):2058-2063.
20. Meredith C, Scott MP, Renwick AB, Price RJ, Lake BG. 2003. Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices. Xenobiotica 33(5):511-527.
21. Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, Morimoto C, Makino I, Tanaka H. 2001. Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J Biol Chem 276(50):47371-47378.
22. Miyata M, Nagata K, Yamazoe Y, Kato R. 1995. Transcriptional elements directing a liver-specific expression of P450/6 beta A (CYP3A2) gene-encoding testosterone 6β-hydroxylase. Arch Biochem Biophys 318(1):71-79.
23. Nguyen TD, Oliva L, Villard PH, Puyoou F, Sauze C, Montet AM, Lacarelle B, Durand A, Montet JC. 1999. CYP2E1 and CYP3A1/2 gene expression is not associated with the ursodeoxycholate effect on ethanol-induced lipoperoxidation. Life Sci 65(11):1103-1113.
24. Paolini M, Pozzetti L, Montagnani M, Potenza G, Sabatini L, Antelli A, Cantelli-Forti G, Roda A. 2002. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP and preservation of BSEP activities. Hepatology 36(2):305-314.
25. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. 2000. Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58(2):361-372.
26. Puglisi CV, Pao J, Ferrara FJ, de Silva JA. 1985. Determination of midazolam (Versed®) and its metabolites in plasma by high-performance liquid chromatography. J Chromatograph 344:199-209.
27. Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34(1-2):83-448.
28. Salen G, Tint GS, Shefer S. 1991. Treatment of cholesterol gallstones with litholytic bile acids. Gastroenterol Clin N Am 20(1):171-182.
29. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. 2001. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276(42):39411-39418.
30. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414-423.
31. Sueyoshi T, Negishi M. 2001. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Ann Rev Pharmacol Toxicol 41:123-143.
32. Teo NH, Scott JM, Neale G, Weir DG. 1980. Effect of bile on vitamin B12 absorption. Br Med J 281(6244):831-833.
33. Trauner M, Graziadei IW. 1999. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13(8):979-996.
34. Tucker GT, Houston JB, Huang SM. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther 70(2):103-114.
35. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. 1994. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73(5):658-661.
36. Yan D, Yang Y, Uchida S, Misaka S, Luo J, Takeuchi K, Inui N, Yamada S, Ohashi K, Watanabe H. 2008. Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. Naunyn-Schmiedeberg's Archiv Pharmacol 377(4-6):629-636.
37. Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. 2006. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. American J Physiology. Gastrointest Liver Phys 290(5):G923-G932.